Similarly, Westbury et al. documented that IL-6 level serum is an early time-dependent biomarker and also demonstrated no significant difference in breast cancer patients’ IL-6 serum levels IL-6 two or five years following RT [40]. This evidence concerns the gene IL6 and breast carcinoma.